Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / VEGFA

VEGFA

Basics

Aliases:
This biomarker is also known as:
  • VEGF,
  • Vascular permeability factor,
  • VPF,
  • VEGF-A,
  • vascular endothelial growth factor A,
  • MVCD1,
  • vascular endothelial growth factor,

View in BioMuta

Description…

Vascular endothelial growth factor (VEGFA or VEGF) is a growth factor and signaling protein involved in the regulation of angiogenesis, vasculogenesis, and endothelial cell grown. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Three VEGFR isoforms have been identified in humans; VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR-2 mediates the majority of cellular responses to VEGF. VEGFR-1 is thought to modulate VEGFR-2 signaling or to act as a dummy/decoy receptor to sequester VEGF away from VEGFR-2.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: VEGFA

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

Preclinical and clinical studies have suggested that VEGFA is important in human breast cancer.

Performance Comment

VEGFA was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Elevated levels of VEGFA in serum and tumor tissue are associated with poor prognosis in patients with lung cancer.

Performance Comment

Levels of angiogenic markers FGF2, ANG, and VEGFA in exhaled breath condensate significantly discriminated between 17 individuals with newly detected non-small cell lung cancer versus stable and exacerbated chronic obstructive pulmonary disease (COPD).

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.